In this episode, we take a deep dive into Compass Pathways (CMPS), a psychedelic-medicines company aiming to treat depression with psilocybin.
To understand Compass Pathways (CMPS ), as a company and as an investment, you have to study 5 things:
What problem is Compass Pathways trying to solve?
CMPS’ clinical trial, treating depression with psilocybin
The founders and leaders of Compass Pathways
Compass’ Financials
Is CMPS stock a good investment for a retail investor?
As the psychedelic stocks sector takes off, Compass Pathways, alongside MindMed (MMED / MMEDF), looks poised to lead the pack. No other psychedelic-medicines company is as advanced in a clinical trial as is Compass Pathways (CMPS). CMPS has a phase 2b trial to test the effectiveness of psilocybin in treating Treatment-Resistant Depression could be game changing, and make for a great investment opportunity.
Let me know in the comments what you guys think. Is Compass Pathways a GOOD INVESTMENT? Will the CMPS stock skyrocket in 2021?
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
Resources:
https://compasspathways.com/
https://www.webmd.com/depression/understanding-depression-basics#1
https://www.psychiatry.org/patients-families/depression/what-is-depression
https://www.nimh.nih.gov/health/statistics/major-depression.shtml
https://www.webmd.com/depression/guide/depression-treatment-options#1
https://www.ncbi.nlm.nih.gov/books/NBK361016/#:~:text=Inotherwordsantidepressantsare,foundtobeequallyeffective
https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-019-2222-4#:~:text=Treatmentresistantdepression(TRD),MDDpatientpopulation1
https://www.beckleyfoundation.org/psilocybin-for-depression-2
https://www.hopkinsmedicine.org/news/newsroom/news-releases/psychedelic-treatment-with-psilocybin-relieves-major-depression-study-shows
https://compasspathways.com/our-research/psilocybin-therapy/about-psilocybin-therapy/#from-subnav
https://psychedelicreview.com/person/ekaterina-malievskaia/
https://compasspathways.com/team-member/george-goldsmith/
https://compasspathways.com/team-member/lars-christian-wilde/
https://www.reuters.com/article/us-compass-pathways-ipo/peter-thiel-backed-compass-pathways-files-for-u-s-ipo-idUSKBN25O31T
https://www.globenewswire.com/news-release/2019/05/15/1825506/0/en/Anxiety-Disorder-and-Depression-Treatment-Market-To-Reach-USD-18-90-Billion-By-2026-Reports-And-Data.html
https://www.treehugger.com/facts-about-magic-mushrooms-4868810
https://psychedelicreview.com/person/ekaterina-malievskaia/
#CompassPathways #CMPS #PsychedelicStocks #MindMed #MMED #MMEDF #PsychedelicStocks #ThePsychedelicInvestor
What Are Psilocybin Spores? Everything You Need to Know and Grow
Culture, EducationIs Compass Pathways a GOOD INVESTMENT? (CMPS stock analysis)
VideosPsychedelic Business News Spotlight: January 08, 2021
BusinessInterview With Kelsey Ramsden, President and CEO of Mind Cure
PodcastsCould Psilocybin End Our Addiction Crisis?
TreatmentNeonMind Takes Psilocybin Therapy Public
BusinessThese 5 Apps Are Made for Taking Psychedelics
Business, CulturePsychedelics Cause Ego Death: What You Need to Know
Culture, ResearchMindMed’s LSD Neutralizer is GENIUS: MindMed Stock’s Massive Opportunity (MMED/MMEDF) 🚀
Videos7 Psychedelic Trend Predictions for 2021
Business